Tag: medical

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients.  China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level. Currently, 4 innovative drugs of CMS have entered into commercialization stage. Meanwhile, continuous advance of products’ clinical development and registration process such as Desidustat ... Read more

expEDIum Announces Successful Partnership with Medical Billing Service & Long-Term Care Medical Group, Inc.

 Expanding its footprint in the healthcare industry, expEDIum is excited to announce the successful collaboration with Long-Term Care Medical Group, Inc. The partnership, initiated in October 2022, has flourished into a dynamic relationship, with Ms. Balwinder Bains, owner of the Medical Billing Service from Fresno, California, leading the charge in seeking innovative solutions to transform their medical billing processes. Facing the challenge of transitioning from a fragmented, legacy system to a more efficient, easily trainable, and scalable solution, Ms. Irene & Balwinder turned to expEDIum for their expertise. After an extensive period of calls and demonstrations, expEDIum gained a deep ... Read more

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro® (the “Product”). Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023. In accordance with the License Agreement, Winhealth Investment gained an exclusive license to register,import, promote, distribute, use and sell the Product in Mainland China, Hong ... Read more

Swedish Medical Center Announces HCA Healthcare Foundation’s $25,000 Grant to Integrated Family Community Services

 Swedish Medical Center, part of HealthONE, announced that the HCA Healthcare Foundation has awarded a $25,000 grant to Integrated Family Community Services (IFCS) in Englewood to support this organization whose work, since its founding in 1964, is focused on alleviating hunger. The grant is one of many awarded across the country as part of HCA Healthcare Foundation’s new Health Equity Catalyst Grant Program. This year, the grants were given to nonprofits addressing food insecurity and providing access to healthy foods. “At Swedish, we’re committed to supporting organizations and collaboratives addressing health inequities,” said Ryan Tobin, CEO, Swedish Medical Center. “Colleagues ... Read more

Perfect Medical Announces Interim Results for FY2023/24

Perfect Medical Health Management Limited (the “Company”, Stock Code: 1830.HK), one of the largest aesthetic medical operators in the world, together with its subsidiaries (collectively referred to the “Group”), is pleased to announce its interim results for the six months ended 30 September 2023. RESULTS HIGHLIGHTS — The Group’s revenue increased by 7.5% to HK$718.1 million, thanks to the momentum growth in revenue in Hong Kong and mainland China amid the abatement of the pandemic in early 2023. — The Group’s EBITDA increased by 5.4% to HK$242.1 million. — The Group’s net profit increased by 10.4% to HK$166.4 million, representing ... Read more